Robert Dudley, Clarus Therapeutics CEO
Struggling penny stock biotech lays off 40% of staffers to stay afloat — for a few more weeks
The clock is ticking for penny stock biotech Clarus Therapeutics.
With $19.2 million left in the bank and $40.5 million of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
